You are here

Pharma Partners Plan First Long-Acting, Two-Drug Injectable Regimen for HIV Patients

Phase III program to begin in mid 2016

ViiV Healthcare has formalized a collaboration with Janssen Sciences Ireland for the phase III investigation and commercialization of long-acting, injectable formulations of cabotegravir (ViiV Healthcare) and rilpivirine (Edurant, Janssen) for maintenance therapy of patients with human immunodeficiency virus-1 (HIV-1) infection who have achieved viral suppression.

While HIV infection is now considered a chronic manageable condition for most individuals, remaining treatment challenges continue to affect the lives of people living with the disease; these challenges include tolerability, safety, dosing schedules, drug interactions, and adherence.

As part of the new agreement, ViiV Healthcare and Janssen expect to start a phase III program to evaluate the efficacy, safety, and tolerability of the long-acting, two-drug injectable regimen in mid 2016.

This is the second development agreement between the two companies. In June 2014, they formed a partnership to develop and commercialize a single-tablet combination of ViiV Healthcare’s integrase strand transfer inhibitor dolutegravir (Tivicay) and Janssen’s rilpivirine, a non-nucleoside reverse transcriptase inhibitor. A phase III clinical trial program to evaluate the safety and efficacy of both medications as maintenance treatment of HIV-1 infection began in May 2015. 

Cabotegravir, an analogue of dolutegravir, is being developed by ViiV Healthcare for the treatment and prevention of HIV infection and is being evaluated as a once-daily oral tablet formulation and as a long-acting nanosuspension formulation for intramuscular injection.

Rilpivirine is used for the treatment of HIV‑1 infection in combination with other antiretroviral agents in antiretroviral treatment-naïve adults with a viral load equal to or less than 100,000 HIV RNA copies/mL. Rilpivirine is approved in the U.S. as a single 25-mg tablet administered once a day with a meal. The product is also available in the U.S. as part of a once-daily fixed-dose antiretroviral combination with tenofovir disoproxil fumarate and emtricitabine (Complera, Gilead Sciences). The most common adverse effects of rilpivirine include depression, headache, insomnia, and rash.

Source: ViiV Healthcare; January 7, 2016.

Recent Headlines

NY Hospitals Required to Implement Protocols in Suspected Cases
Presence of BOK Protein Key for Positive Treatment Response
Patient Access to Inhaler Use Data Could Improve Asthma Management
Overall Survival 4.3 Months’ vs. 1.5 Months for Traditional Regimens
Primary Immunodeficiencies Affect 250,000 People in U.S.
More Than 25% of Patients Responded to Xpovio/Dexamethasone Combo
Attacks Cancerous Cells, Leaves Healthy Tissues Alone